The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MEDI-573 as a novel approach to IGF-1R and IR-A signaling inhibition by blocking IGF ligands: Phase I PK/PD, safety data, and disease linkage studies in breast cancer.
P. Haluska
Consultant or Advisory Role - MedImmune (U)
Research Funding - MedImmune
J. Huang
Employment or Leadership Position - MedImmune
B. Lam
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
M. Liang
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
W. Huang
Employment or Leadership Position - MedImmune
P. LoRusso
Research Funding - MedImmune
M. E. Menefee
Research Funding - MedImmune
T. LaVallee
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Y. Yao
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
J. Viner
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca; MedImmune